anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
We previously characterized hemisphere-specific motor control deficits in the non-paretic arm of unilaterally lesioned stroke survivors. Our preliminary data indicate these deficits are substantial and functionally limiting in patients with severe paresis. We have specifically designed an intervention to remediate the hemisphere-specific deficits in the less-impaired arm, using a virtual-reality platform, and then follow this training with manipulation training of a variety of real objects, designed to facilitate generalization and transfer to functional behaviors encountered in the natural environment. We propose a 2-site, two-group randomized intervention with a treatment group, which will receive unilateral training of the less-impaired arm, through our Virtual Reality and Manipulation Training (VRMT) protocol. This intervention protocol is grounded in the premise that targeted remediation of fundamental control deficits exhibited by the less-impaired arm will generalize and transfer beyond practiced tasks to performance of activities of daily living (ADL). This approach contrasts with the more pragmatic approach of task-specific training of essential ADL's, which is limited in scope, more cumbersome, and ignores known fundamental motor control deficits. Our control group will receive conventional intervention, guided by recently released practice guidelines for upper limb intervention in adult stroke. The impact of the proposed research is that we address persistent functional performance deficits in chronic stroke patients with severe paresis, who's less-impaired arm impairments are generally ignored in most current rehabilitation protocols. Our first aim addresses the overall effectiveness of this intervention, relative to our control group: To determine whether non-paretic arm VRMT in chronic stroke survivors with severe paresis will produce durable improvements in less-impaired arm motor performance that will generalize to improve functional activities and functional independence to a greater extent than conventional therapy focused on the paretic arm. Our second aim focuses on the mechanistic basis of potential training-related improvements in motor performance: To determine whether intervention-induced improvements in less-impaired arm performance are associated with improvements in hemisphere-specific reaching kinematics. Finally, our third aim monitors for potential negative effects of our experimental intervention on paretic arm impairment.
Controlled Substance Class– Sertraline hydrochloride is not a controlled substance.

Physical and Psychological Dependence–In a placebo-controlled, double-blind, randomized study of the comparative abuse liability of Sertraline hydrochloride, alprazolam, and d-amphetamine in humans, Sertraline hydrochloride did not produce the positive subjective effects indicative of abuse potential, such as euphoria or drug liking, that were observed with the other two drugs. Premarketing clinical experience with Sertraline hydrochloride did not reveal any tendency for a withdrawal syndrome or any drug-seeking behavior. In animal studies sertraline hydrochloride does not demonstrate stimulant or barbiturate-like (depressant) abuse potential. As with any CNS active drug, however, physicians should carefully evaluate patients for history of drug abuse and follow such patients closely, observing them for signs of sertraline hydrochloride misuse or abuse (e.g., development of tolerance, incrementation of dose, drug-seeking behavior).

Please review the manufacturer's complete drug information available from the FDA at www.fda.gov   
Permanent Link: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf71d1b9-5ebb-429f-a07f-a87cd168250f
Older African Americans-especially those with lower income and those living in urban neighborhoods- have a greater risk of Alzheimer's disease (AD) compared to the general population. This health disparity is attributable, in part, to modifiable factors including insufficient levels of aerobic exercise. However, not everyone gains the same degree of neuroprotection from exercise. For the proposed project, the investigators plan to investigate genetic risk as a novel source of response heterogeneity to exercise interventions in African Americans. Previously, the investigators demonstrated that five months of twice-weekly cardio-dance exercise can increase the dynamic rearrangement (or "neural flexibility") of resting-state networks within the medial temporal lobe (MTL), one of the earliest brain regions impacted by AD. Moreover, this improved neural flexibility mediates intervention-related improvements in generalization, the ability to apply past learning to novel task demands. Given our earlier findings that generalization is impaired in preclinical AD, these results suggest a novel circuit-level mechanism, MTL neural flexibility, through which exercise may reduce risk for dementia. Moreover, the investigators discovered that the cognitive benefits of exercise in older African Americans are diminished in those with a risk variant of the ABCA7 (rs3764650) gene. Two key limitations to our previous exercise studies were: (1) interventions limited to two 60-minute classes/week, below the recommended 150 minutes/week, and (2) too few participants to evaluate the effect of ABCA7 on exercise-induced changes on neural flexibility. The investigators propose to recruit 280 sedentary older African Americans, ages 60 and above, to be randomized to one of two equally engaging six-month interventions, a Cardio Dance Fitness (CDF) intervention, and a Strength, Flexibility, \& Balance active control. All participants will undergo-at enrollment and post-intervention-health assessments, cognitive tests, and structural and functional magnetic resonance imaging (fMRI), and a blood-draw to assess amyloid (Aβ 42/40) and tau (p-tau231, p-tau181). This will enable us to test: 1) the effect of the CDF intervention on a cognitive marker of AD risk, generalization; 2) the effect of the CDF intervention on a fMRI biomarker of AD, neural flexibility, and determine whether improvements in neural flexibility mediate improvements in generalization; and 3) whether ABCA7 genotypic variations moderate the efficacy of the CDF intervention for reducing AD risk. Impact: This work lays the foundation for future larger clinical trials to develop personalized exercise prescriptions for older African Americans with varying genetic, health, and social-determinant risk profiles, so as to optimize the impact of this low-cost non-pharmaceutical intervention for improving their brain health.
Facial transplantations have become a clinical reality as the last reconstructive option in severely disfigured patients. To date, clinical outcomes remain unclear. The purpose of this paper was to analyse the outcomes in facial transplantation (FT) and determine the risks and benefits of FT based on short- and long-term outcomes. An electronic literature search was performed across PubMed, EMBASE and the Cochrane Central Register for Controlled Trials (CENTRAL) databases to capture all the relevant records relating to outcomes in FTs from 2005 to 2021. Articles for inclusion were decided upon pre-defined inclusion and exclusion criteria. A total of 48 FTs has been performed to date. A total of 90 studies met the eligibility criteria and were included in the outcome analysis. Studies were analysed based on each of the 48 cases and outcomes categorised into short-term (<36 months) and long-term (>36 months) outcomes. Primary outcomes included patient and graft survival and secondary outcomes included functional, surgical revision events, immunological, medical complications, aesthetics, psychosocial and quality of life. Mortality rate, infection and malignancy incidence remain high, and patients should be fully informed of the potential life-threatening complications. FTs improve outcomes such as quality of life and psychosocial recovery in the short- and long-term. Outcomes remain under-reported in peer-review journals.
To retrospectively assess the effectiveness of deep learning (DL) model, based on breast magnetic resonance imaging (MRI), in predicting preoperative lymphovascular invasion (LVI) status in patients diagnosed with invasive breast cancer who have negative axillary lymph nodes (LNs). Data was gathered from 280 patients, including 148 with LVI-positive and 141 with LVI-negative lesions. These patients had undergone preoperative breast MRI and were histopathologically confirmed to have invasive breast cancer without axillary LN metastasis. The cohort was randomly split into training and validation groups in a 7:3 ratio. Radiomics features for each lesion were extracted from the first post-contrast dynamic contrast-enhanced (DCE)-MRI. The Least Absolute Shrinkage and Selection Operator (LASSO) regression method and logistic regression analyses were employed to identify significant radiomic features and clinicoradiological variables. These models were established using four machine learning (ML) algorithms and one DL algorithm. The predictive performance of the models (radiomics, clinicoradiological, and combination) was assessed through discrimination and compared using the DeLong test. Four clinicoradiological parameters and 10 radiomic features were selected by LASSO for model development. The Multilayer Perceptron (MLP) model, constructed using both radiomic and clinicoradiological features, demonstrated excellent performance in predicting LVI, achieving a high area under the curve (AUC) of 0.835 for validation. The DL model (MLP-radiomic) achieved the highest accuracy (AUC = 0.896), followed by DL model (MLP-combination) with an AUC of 0.835. Both DL models were significantly superior to the ML model (RF-clinical) with an AUC of 0.720. The DL model (MLP), which integrates radiomic features with clinicoradiological information, effectively aids in the preoperative determination of LVI status in patients with invasive breast cancer and negative axillary LNs. This is beneficial for making informed clinical decisions.
RIPK1, a receptor-interacting serine/threonine protein kinase, plays a crucial role in maintaining cellular and tissue homeostasis by integrating inflammatory responses and cell death signaling pathways including apoptosis and necroptosis, which have been implicated in diverse physiological and pathological processes. Suppression of RIPK1 activation is a promising strategy for restraining the pathological progression of many human diseases. Neuroinflammation and neuronal apoptosis are two pivotal factors in the pathogenesis of brain injury following subarachnoid hemorrhage (SAH). In this study, we established in vivo and in vitro models of SAH to investigate the activation of RIPK1 kinase in both microglia and neurons. We observed the correlation between RIPK1 kinase activity and microglia-mediated inflammation as well as neuronal apoptosis. We then investigated whether inhibition of RIPK1 could alleviate neuroinflammation and neuronal apoptosis following SAH, thereby reducing brain edema and ameliorating neurobehavioral deficits. Additionally, the underlying mechanisms were also explored. Our research findings revealed the activation of RIPK1 kinase in both microglia and neurons following SAH, as marked by the phosphorylation of RIPK1 at serine 166. The upregulation of p-RIPK1(S166) resulted in a significant augmentation of inflammatory cytokines and chemokines, including TNF-α, IL-6, IL-1α, CCL2, and CCL5, as well as neuronal apoptosis. The activation of RIPK1 in microglia and neurons following SAH could be effectively suppressed by administration of Nec-1 s, a specific inhibitor of RIPK1. Consequently, inhibition of RIPK1 resulted in a downregulation of inflammatory cytokines and chemokines and attenuation of neuronal apoptosis after SAH in vitro. Furthermore, the administration of Nec-1 s effectively mitigated neuroinflammation, neuronal apoptosis, brain edema, and neurobehavioral deficits in mice following SAH. Our findings suggest that inhibiting RIPK1 kinase represents a promising therapeutic strategy for mitigating brain injury after SAH by attenuating RIPK1-driven neuroinflammation and neuronal apoptosis.
The invention relates to an alcohol relieving composition and a preparation method thereof. The composition of the invention is made of raw materials of homology of medicine and food such as semen hoveniae, kudzu root, gyrophora, medlar, chrysanthemum and liquorice. The details of the particular preparation method are seen in an instruction book. The composition has the advantages that: on the basis of prior alcohol relieving formulation selection, the composition comprises plants capable of protecting liver, preventing oxidation and detoxicating and a plurality of biological active ingredients such as saponin, flavone, coumarin, alkaloid, amylase and amine acid; the pharmacodynamic test shows that the alcohol relieving composition has evident functions for reducing the content of alcohol  in blood and shortening the drunk time. Moreover, all the compositions are made of raw materials of homology of medicine and food, not only the effectiveness as the medicine is kept, but also the security as an edible drug is guaranteed. Meanwhile, the preparation method is convenient and simple as well as easy to implement and is suitable for the industrial production.
Ovarian cancer, particularly high grade serous ovarian cancer (HGSC), is the major cause of death in gynaecological malignancies worldwide, but does not benefit significantly from the recent advances in cancer immunotherapy. Although lymphocyte infiltration HGSC is associated with higher survival rates, the nature of the antigen that can elicit an immune response against HGSC is not yet clear. Described herein are novel Tumor Specific Antigens (TSAs) shared by a large proportion of ovarian tumors. Most TSAs described herein (> 80%) are derived from unmutated genomic sequences that are abnormally expressed, such as introns and intergenic sequences that are not expressed in normal tissues. Nucleic acids, compositions, cells and vaccines derived from these TSAs are described. Also described are uses of TSA, nucleic acids, compositions, cells and vaccines for treating ovarian cancer.
Patients who undergo thoracoscopic lobectomy are often at an elevated risk of opioid-related complications due to their reliance on opioids. This overdependence not only decelerates the postoperative recovery process but also significantly increases healthcare costs. Although there is a surge of interest in opioid-free anesthetic analgesia (OFA) for its potential to reduce adverse outcomes associated with opioid use, there is a dearth of randomized controlled trials examining the efficacy of postoperative analgesia in patients undergoing thoracoscopic surgery. Consequently, the actual effectiveness of OFA in improving postoperative pulmonary complications and facilitating patient recovery remains unclear. Its application is still in the exploratory phase, with clinical practice lacking definitive guidelines to endorse or discard OFA as an alternative for postoperative analgesia in thoracoscopic surgery.

To bridge this knowledge gap and evaluate the perioperative analgesic efficacy of OFA compared to traditionally used opioids in selected cancer patients undergoing thoracoscopic surgery, investigators have designed a randomized controlled trial. Utilizing an open-label, randomized, controlled study methodology, this trial aims to explore a opioid-free, safe, and effective analgesic approach for thoracic surgery. It also seeks to provide clinical guidance for the implementation of opioid-free or reduced-opioid postoperative analgesia in other thoracic procedures, aiming to optimize postoperative pain management for patients and ultimately enhance the overall patient recovery experience.
PURPOSE:To obtain the subject powder and a cosmetic containing the same, capable of keeping excellent spreadability even after collapse and having excellent transferability to a coating object, resistance to caking, etc., by granulating spherical silicic anhydride having a specific particle diameter with a polymer in the form of coagulated particles having a specific diameter. CONSTITUTION:Spherical silicic anhydride having an average particle diameter of 0.1-10mum or the silicic anhydride and other cosmetic powder having an average particle diameter of 0.01-20mum are granulated to an average coagulated particle diameter of 20-200mum with 0.1-30 pts.wt., preferably 1-10 pts.wt. (based on 100 pts.wt. of the sum of the silicic anhydride, etc.) of a water-soluble polymer and/or a hydrophobic polymer to obtain the objective pressure-collapsible spherical powder. Since the spherical powder is collapsed by make-up operation to form primary particles of spherical silicic anhydride having small particle diameter, the cosmetic compound with the spherical powder has excellent spreadability, gives a uniform make-up layer and soft and natural finished skin without giving rough feeling to the skin, exhibits excellent dispersibility and has caking resistance, and has excellent collapsibility by making-up handy pressure even after spreading an human skin.
The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. TAT113 polypeptides comprising the amino acid sequence of SEQ ID NO: 2 are disclosed. Antibodies that bind TAT113 polypeptides, including monoclonal, chimeric, humanized, single chain, and other antibodies, and fragments thereof, are disclosed. Methods of identifying antibodies that bind epitopes bound by such antibodies, including the antibodies produced by hybridoma cell lines disclosed in the application, are provided, wherein the ability of one antibody to block the binding of another antibody to a TAT113 polypeptide indicates that one antibody binds to an epitope bound by the other antibody. Methods of diagnosing the presence of a tumor in a mammal using such antibodies are disclosed, wherein detection of the formation of a complex between an antibody and a protein in a test sample is indicative of the presence of a tumor in said mammal. Methods of inhibiting the growth of a cancer cell that expresses a protein comprising the amino acid sequence of SEQ ID NO: 2, are disclosed, where the binding of the antibody to the protein inhibits the growth of the cell. Methods of inhibiting the growth of a cancer cell include methods wherein the antibody binds to the epitope bound by an antibody produced by a disclosed hybridoma cell line.
A preparing method of a medicine for treating psoriasis is provided. The method includes following steps: weighing caulis polygoni multiflori, alate senna leaf, short greenbrier root, christina loosestrife, seabuckthorn fruit, inonotus obliquus, pilosella-leaved drymoglossum herb, and salvia miltiorrhiza according to a weight ratio, smashing, adding ethanol having a concentration of 75% according to a material liquid ratio of 1:8, performing three times of reflux extraction with each time of reflux extraction being performed for 2 h, combining reflux liquids, concentrating to obtain extract having a density of 1.28-1.32 (at 25 DEG C), drying the extract, smashing the extract into fine powder, weighing black sesame seed with a certain weight, preparing the black sesame seed into powder having a size of 200 meshes, mixing the fine powder and the powder, and encapsulating to obtain a capsule. Medicine components in the medicine are cooperative. The medicine has functions of calming nerves, nourishing blood, treating depletion of body fluid causing lack of blood, clearing heat and toxins, activating blood circulation and tonifying qi. Synergistic effects of medicine components in the medicine are obvious. The medicine is obvious in curative effects for treatment of psoriasis.
In the sham group a 18 gauge introducer and probe will be placed but no RF intervention will be applied. The generator will be turned on without connection to the probe for 150 seconds and the sound of the generator will be mimicked with a recording. The position of the needle will not be checked by fluoroscopy; however, the intervention team will position the fluoroscopy arm and mention the acquisition of the fluoroscopic image to the patient. This way no unnecessary radiation is used.
Apparatus and an associated method for monitoring concentration of analyte-specific receptors, such as glucose in blood includes a porous hollow sensor body which defines a processing chamber containing a plurality of porous beads, and an analyte, such as glucose-specific receptors bound to helper molecules. A light source causes exciting light to impinge on the sensor body. When glucose is present in a certain concentration within the sensor body chamber, responsive emitted fluorescent light will emerge and may be detected in order to determine the analyte concentration. The analyte-specific receptors may be bound initially to the helper molecules within pores of the beads when the certain level of analyte is not present in the sensor body chamber. The presence of increased levels of analyte in the chamber will cause the analyte-specific receptors to bind thereto and thereby increase the intensity of the emitted fluorescent light thereby providing an indication of the amount of analyte in the blood. When bound to the analyte, the analyte-specific receptors will be positioned outside of the pores in the beads and, therefore, be in more substantial contact with the excitation light. The porous beads are preferably made of opaque material or may be dye-labeled to minimize fluorescent background light levels to minimize detection of the fluorochrome-labeled glucose-specific receptor when the species reside within the porous beads. The invention may be employed in a glucose detector, as well as with other analytes.
Patients and methods Thirty control healthy individuals and 200 patients with uncomplicated, essential hypertension were enrolled and followed up for 3 months in a controlled randomized study. All subjects' health status was evaluated by a complete medical examination. All BP measurements were made with calibrated mercury manometers (Korotkoff I and V). Three separate measurements were taken at least 2 min apart and the average of these values was calculated. Subjects' height and weight were recorded in the fasting state with the subjects wearing only light clothes and without shoes and BMI was calculated using the equation (BMI = weight (kg)/height (m)2). Patients, of both sexes with mild to moderate essential hypertension (diastolic blood pressure \[DBP\] \>80 and ≤100 mmHg after a 2-week wash-out period, SBP systolic blood pressure\>120 and 160 mmHg). Patients were randomly assigned into two groups using a computer-generated random number: Group I treated with valsartan (160 mg/d, n = 100), Group II amlodipine (10 mg/d, n = 100). Another 30 healthy subjects are enrolled as control group (Group III). Subjects in group I and II were asked to maintain their usual dietary and physical activity habits throughout the study. Treatment tolerability was assessed at each follow-up visit.
OBJECTIVES: I. Estimate the objective response rate of PCNSL in AIDS patients treated with hydroxyurea. II. Investigate whether levels of Epstein-Barr virus (EBV) DNA in the blood or cerebral spinal fluid are correlates of PCNSL disease activity.

OUTLINE: This is an open label pilot study. Patients receive oral hydroxyurea tid. A course of hydroxyurea consists of 4 weeks of therapy. On day 28, after the first course of treatment, tumor size is analyzed by MRI. If no reduction in tumor size is seen on day 28, hydroxyurea dose is increased. If a CR or PR is demonstrated, patients continue on the same treatment at the original dose. MRI evaluation is again taken on day 56 of treatment. Patients with progressive disease at this evaluation are considered to have no treatment response.

PROJECTED ACCRUAL: 15-25 patients will be enrolled. Approximately 8-10 patients will be accrued annually.